APAC Stroke Market - Industry Trends and Forecast to 2031
Europe stroke market is projected to register a CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation:
Europe Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland and Rest of Europe) – Industry trends and forecast to 2030
Overview of Europe Stroke Market Dynamics
Drivers
• Rising incidences of stroke
• Increasing number of patients with hypertension and coronary heart diseases
Restraints
• High cost associated with treatment of stroke
• Side-effects associated with medication
Opportunities
• Expansion of telemedicine and remote monitoring
• Innovative therapies in pipeline for stroke treatment
Market Players
Some of the major market players operating in the Europe stroke market are:
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH.
• F. Hoffmann-La Roche Ltd
• DAIICHI SANKYO COMPANY, LIMITED.
• Sanofi
• Johnson & Johnson Services, Inc.
• Bayer AG
• Sandoz AG
• Pfizer Inc.
• Medtronic
• Abbott
• Viatris Inc.
• AstraZeneca
• Penumbra, Inc.
• GLENMARK PHARMACEUTICALS LTD
• Fresenius Kabi USA
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of The Europe Stroke Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Type Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Market Application Coverage Grid
- 2.11 Vendor Share Analysis
- 2.12 Secondary Sources
- 2.13 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Pestel's Model
- 4.2 Porter's 5 Forces
- 5 Epidemiology
- 6 Europe Stroke Market, Regulatory Framework
- 6.1 Regulation In U.S
- 6.2 Regulation In Europe
- 6.3 Regulation In China
- 6.4 Regulation In Japan
- 6.5 Regulation In South Africa 70
- 7 Market Overview
- 7.1 Drivers
- 7.1.1 Rising Incidences Of Stroke
- 7.1.2 Increasing Number Of Patients With Hypertension And Coronary Heart Diseases
- 7.1.3 Increasing Diabetic And Obese Population
- 7.1.4 Advancements In Medical Technology For Stroke Treatment
- 7.2 Restraints
- 7.2.1 High Cost Associated With Treatment Of Stroke
- 7.2.2 Side-effects Associated With Medication
- 7.3 Opportunities
- 7.3.1 Expansion Of Telemedicine And Remote Monitoring
- 7.3.2 Innovative Therapies In Pipeline For Stroke Treatment
- 7.4 Challenges
- 7.4.1 Inaccurate Diagnosis Of Strokes S
- 7.4.2 Complications In Managing Stroke In Patients With Multiple Chronic Conditions
- 8 Europe Stroke Market, By Type
- 8.1 Overview
- 8.2 Ischemic Stroke
- 8.2.1 Thrombotic (Cerebral Thrombosis)
- 8.2.2 Embolic (Cerebral Embolism)
- 8.3 Hemorrhagic Stroke
- 8.3.1 Subarachnoid Hemorrhage
- 8.3.2 Intracerebral Hemorrhage
- 8.4 Transient Ischemic Attack (Tia)
- 9 Europe Stroke Market, By Treatment
- 9.1 Overview
- 9.2 Medication
- 9.2.1 By Class
- 9.2.1.1 Blood Pressure Medicines
- 9.2.1.1.1 Angiotensin-converting Enzyme (Ace) Inhibitors
- 9.2.1.1.1.1 Ramipril
- 9.2.1.1.1.2 Lisinopril
- 9.2.1.1.1.3 Enalapril
- 9.2.1.1.1.4 Perindopril
- 9.2.1.1.1.5 Other 98
- 9.2.1.1.2 Diuretics
- 9.2.1.1.2.1 Indapamide
- 9.2.1.1.2.2 Bendroflumethiazide
- 9.2.1.1.2.3 Spironolactone
- 9.2.1.1.2.4 Amiloride
- 9.2.1.1.2.5 Other
- 9.2.1.1.3 Calcium Channel Blockers
- 9.2.1.1.3.1 Amlodipine
- 9.2.1.1.3.2 Nifedipine
- 9.2.1.1.3.3 Verapamil
- 9.2.1.1.3.4 Nicardipine
- 9.2.1.1.3.5 Felodipine
- 9.2.1.1.3.6 Nimodipine
- 9.2.1.1.3.7 Other
- 9.2.1.1.4 Beta Blockers
- 9.2.1.1.4.1 Atenolol
- 9.2.1.1.4.2 Bisoprolol
- 9.2.1.1.4.3 Labetolol
- 9.2.1.1.4.4 Other
- 9.2.1.1.5 Alpha Blockers
- 9.2.1.1.5.1 Doxazosin
- 9.2.1.1.5.2 Other
- 9.2.1.1.6 Others
- 9.2.1.1 Antiplatelet Drugs
- 9.2.1.1.1 Aspirin
- 9.2.1.1.2 Clopidogrel
- 9.2.1.1.3 Dipyridamole
- 9.2.1.1.4 Ticlopidine
- 9.2.1.1.5 Others
- 9.2.1.2 Anticoagulants
- 9.2.1.2.1 Warfarin
- 9.2.1.2.2 Apixaban
- 9.2.1.2.3 Dabigatran
- 9.2.1.2.4 Heparin
- 9.2.1.2.5 Rivaroxaban
- 9.2.1.2.6 Others
- 9.2.1.3 Tissue Plasminogen Activator (Tpa)
- 9.2.1.3.1 Alteplase
- 9.2.1.3.2 Tenecteplase
- 9.2.1.3.3 Reteplase
- 9.2.1.3.4 Anistreplase
- 9.2.1.3.5 Others
- 9.2.1.4 Statins
- 9.2.1.4.1 Atorvastatin
- 9.2.1.4.2 Simvastatin
- 9.2.1.4.3 Lovastatin
- 9.2.1.4.4 Rosuvastatin
- 9.2.1.4.5 Fluvastatin
- 9.2.1.4.6 Pravastatin
- 9.2.1.4.7 Pitavastatin
- 9.2.1.4.8 Others
- 9.2.1.5 Vitamin K
- 9.2.1.6 Supportive Medication
- 9.2.1.6.1 Nutritional Supplements
- 9.2.1.6.2 Antipyretics
- 9.2.1.6.3 Others
- 9.2.2 By Drug Type
- 9.2.2.1 Generics
- 9.2.2.2 Branded
- 9.2.2.2.1 Eliquis
- 9.2.2.2.2 Pradaxa
- 9.2.2.2.3 Activase
- 9.2.2.2.4 Aspirin
- 9.2.2.2.5 Plavix
- 9.2.2.2.6 Aggrenox
- 9.2.2.2.7 Others
- 9.2.3 By Route Of Administration
- 9.2.3.1 Oral
- 9.2.3.1.1 Tablet
- 9.2.3.1.2 Capsules
- 9.2.3.1.3 Others
- 9.2.3.2 Parenteral
- 9.2.3.2.1 Intravenous
- 9.2.3.2.2 Subcutaneous
- 9.2.3.3 Others
- 9.2.4 By Mode Of Purchase
- 9.2.4.1 Prescription
- 9.2.4.2 Over The Counter (Otc) 115
- 9.2.5 By Therpay Type
- 9.2.5.1 Combination Therapy
- 9.2.5.2 Monotherapy
- 9.3 Surgery
- 9.3.1 Embolic Coils
- 9.3.2 Aspiration Catheters
- 9.3.3 Stent Retriever
- 9.3.4 Surgical Clipping
- 9.3.5 Others
- 9.4 Other Therapy
- 9.4.1 Physical Therapy
- 9.4.2 Occupational Therapy
- 9.4.3 Speech Therapy
- 9.4.4 Others
- 10 Europe Stroke Market, By Diagnosis
- 10.1 Overview
- 10.2 Imaging Test
- 10.2.1 Computerized Tomography (Ct) Scan
- 10.2.2 Magnetic Resonance Imaging (Mri)
- 10.2.3 Carotid Ultrasound
- 10.2.4 Cerebral Angiogram
- 10.3 Blood Test
- 10.4 Echocardiogram
- 10.5 Lumbar Puncture
- 10.6 Others
- 11 Europe Stroke Market, By Gender
- 11.1 Overview
- 11.2 Female
- 11.3 Male
- 12 Europe Stroke Market, By End User
- 12.1 Overview
- 12.2 Hospitals & Clinics
- 12.3 Specialty Clinics
- 12.4 Ambulatory Surgical Center
- 12.5 Homecare
- 12.6 Laboratories
- 12.7 Others 142
- 13 Europe Stroke Market, By Distribution Channel
- 13.1 Overview
- 13.2 Direct
- 13.3 Retail
- 13.4 Online
- 14 Europe Stroke Market, By Region
- 14.1 Europe
- 14.1.1 Germany
- 14.1.2 U.K.
- 14.1.3 France
- 14.1.4 Russia
- 14.1.5 Italy
- 14.1.6 Spain
- 14.1.7 Turkey
- 14.1.8 Poland
- 14.1.9 Belgium
- 14.1.10 Netherlands
- 14.1.11 Switzerland
- 14.1.12 Denmark
- 14.1.13 Sweden
- 14.1.14 Norway
- 14.1.15 Finland
- 14.1.16 Rest Of Europe
- 15 Europe Stroke Market, Company Landscape
- 15.1 Company Share Analysis: Europe
- 16 Swot Analysis
- 17 Company Profiles
- 17.1 Bristol-myers Squibb Company
- 17.1.1 Company Snapshot
- 17.1.2 Revenue Analysis
- 17.1.3 Company Share Analysis
- 17.1.4 Product Portfolio
- 17.1.5 Recent Development 341
- 17.2 Boehringer Ingelheim International Gmbh
- 17.2.1 Company Snapshot
- 17.2.2 Product Portfolio
- 17.2.3 Company Share Analysis
- 17.2.4 Recent Development
- 17.3 F. Hoffmann-la Roche Ltd
- 17.3.1 Company Snapshot
- 17.3.2 Revenue Analysis
- 17.3.3 Company Share Analysis
- 17.3.4 Product Portfolio
- 17.3.5 Recent Development
- 17.4 Daiichi Sankyo Company, Limited
- 17.4.1 Company Snapshot
- 17.4.2 Revenue Analysis
- 17.4.3 Company Share Analysis
- 17.4.4 Product Portfolio
- 17.4.5 Recent Development
- 17.5 Sanofi
- 17.5.1 Company Snapshot
- 17.5.2 Revenue Analysis
- 17.5.3 Company Share Analysis
- 17.5.4 Product Portfolio
- 17.5.5 Recent Development
- 17.6 Abbott
- 17.6.1 Company Snapshot
- 17.6.2 Revenue Analysis
- 17.6.3 Product Portfolio
- 17.6.4 Recent Development
- 17.7 Amneal Pharmaceuticals Llc
- 17.7.1 Company Snapshot
- 17.7.2 Revenue Analysis
- 17.7.3 Product Portfolio
- 17.7.4 Recent Development
- 17.8 Astrazeneca
- 17.8.1 Company Snapshot
- 17.8.2 Revenue Analysis
- 17.8.3 Product Portfolio
- 17.8.4 Recent Development 17.9 Bayer Ag
- 17.9.1 Company Snapshot
- 17.9.2 Revenue Analysis
- 17.9.3 Product Portfolio
- 17.9.4 Recent Development
- 17.10 Fresenius Se & Co. Kgaa
- 17.10.1 Company Snapshot
- 17.10.2 Revenue Analysis
- 17.10.3 Product Portfolio
- 17.10.4 Recent Development
- 17.11 Glenmark Pharmaceuticals Ltd.
- 17.11.1 Company Snapshot
- 17.11.2 Revenue Analysis
- 17.11.3 Product Portfolio
- 17.11.4 Recent Development
- 17.12 Johnson & Johnson Services, Inc.
- 17.12.1 Company Snapshot
- 17.12.2 Revenue Analysis
- 17.12.3 Product Portfolio
- 17.12.4 Recent Development
- 17.13 Lupin
- 17.13.1 Company Snapshot
- 17.13.2 Revenue Analysis
- 17.13.3 Product Portfolio
- 17.13.4 Recent Development
- 17.14 Medtronic
- 17.14.1 Company Snapshot
- 17.14.2 Revenue Analysis
- 17.14.3 Product Portfolio
- 17.14.4 Recent Development
- 17.15 Oxford Laboratories Pvt. Ltd.
- 17.15.1 Company Snapshot
- 17.15.2 Product Portfolio
- 17.15.3 Recent Development
- 17.16 Penumbra, Inc.
- 17.16.1 Company Snapshot
- 17.16.2 Revenue Analysis
- 17.16.3 Product Portfolio
- 17.16.4 Recent Development 17.17 Pfizer Inc.
- 17.17.1 Company Snapshot
- 17.17.2 Revenue Analysis
- 17.17.3 Product Portfolio
- 17.17.4 Recent Development
- 17.18 Sandoz Group Ag (Subsidiary Of Novartis Ag)
- 17.18.1 Company Snapshot
- 17.18.2 Revenue Analysis
- 17.18.3 Product Portfolio
- 17.18.4 Recent Development
- 17.19 Teva Pharmaceuticals Usa, Inc.
- 17.19.1 Company Snapshot
- 17.19.2 Revenue Analysis
- 17.19.3 Product Portfolio
- 17.19.4 Recent Development
- 17.20 Viatris Inc.
- 17.20.1 Company Snapshot
- 17.20.2 Revenue Analysis
- 17.20.3 Product Portfolio
- 17.20.4 Recent Development
- 18 Questionnaire
- 19 Related Reports
- List Of Tables
- Table 1 Europe Stroke Market, By Type, 2022-2030 (Usd Thousand)
- Table 2 Europe Ischemic Stroke In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 3 Europe Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 4 Europe Hemorrhagic Stroke In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 5 Europe Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 6 Europe Transient Ischemic Attack (Tia) In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 7 Europe Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 8 Europe Medication In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 9 Europe Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 10 Europe Blood Pressure Medicines In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 11 Europe Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 12 Europe Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 13 Europe Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 14 Europe Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 15 Europe Alpha Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 16 Europe Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 17 Europe Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 18 Europe Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 19 Europe Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 20 Europe Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 21 Europe Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 22 Europe Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 23 Europe Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 24 Europe Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 25 Europe Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 26 Europe Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
- Table 27 Europe Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
- Table 28 Europe Surgery In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 29 Europe Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 30 Europe Other Therapy In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 31 Europe Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 32 Europe Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
- Table 33 Europe Imaging Test In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 34 Europe Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 35 Europe Blood Test In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 36 Europe Echocardiogram In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 37 Europe Lumbar Puncture In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 38 Europe Others In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 39 Europe Stroke Market, By Gender, 2021-2030 (Usd Thousand)
- Table 40 Europe Female In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 41 Europe Male In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 42 Europe Stroke Market, By End User, 2021-2030 (Usd Thousand)
- Table 43 Europe Hospitals & Clinics In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 44 Europe Specialty Clinics In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 45 Europe Ambulatory Surgical Center In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 46 Europe Homecare In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 47 Europe Laboratories In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 48 Europe Others In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 49 Europe Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
- Table 50 Europe Direct In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 51 Europe Retail In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 52 Europe Online In Stroke Market, By Region, 2021-2030 (Usd Thousand)
- Table 53 Europe Stroke Market, By Country, 2021-2030 (Usd Thousand)
- Table 54 Europe Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 55 Europe Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 56 Europe Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 57 Europe Stroke Market, By Diagnosis And Treatment, 2021-2030 (Usd Thousand)
- Table 58 Europe Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 59 Europe Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 60 Europe Blood Pressure Medicine In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 61 Europe Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 62 Europe Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 63 Europe Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 64 Europe Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 65 Europe Alpha-blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 66 Europe Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 67 Europe Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 68 Europe Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 69 Europe Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 70 Europe Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 71 Europe Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 72 Europe Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 73 Europe Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 74 Europe Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 75 Europe Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 76 Europe Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
- Table 77 Europe Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
- Table 78 Europe Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 79 Europe Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 80 Europe Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
- Table 81 Europe Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 82 Europe Stroke Market, By Gender, 2021-2030 (Usd Thousand)
- Table 83 Europe Stroke Market, By End User, 2021-2030 (Usd Thousand)
- Table 84 Europe Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
- Table 85 Germany Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 86 Germany Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 87 Germany Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 88 Germany Stroke Market, By Diagnosis And Treatment, 2021-2030 (Usd Thousand)
- Table 89 Germany Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 90 Germany Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 91 Germany Blood Pressure Medicine In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 92 Germany Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 93 Germany Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 94 Germany Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 95 Germany Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 96 Germany Alpha-blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 97 Germany Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 98 Germany Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 99 Germany Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 100 Germany Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 101 Germany Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 102 Germany Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 103 Germany Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 104 Germany Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 105 Germany Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 106 Germany Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 107 Germany Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
- Table 108 Germany Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
- Table 109 Germany Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 110 Germany Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 111 Germany Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
- Table 112 Germany Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 113 Germany Stroke Market, By Gender, 2021-2030 (Usd Thousand)
- Table 114 Germany Stroke Market, By End User, 2021-2030 (Usd Thousand)
- Table 115 Germany Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
- Table 116 U.K. Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 117 U.K. Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 118 U.K. Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 119 U.K. Stroke Market, By Diagnosis And Treatment, 2021-2030 (Usd Thousand)
- Table 120 U.K. Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 121 U.K. Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 122 U.K. Blood Pressure Medicine In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 123 U.K. Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 124 U.K. Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 125 U.K. Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 126 U.K. Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 127 U.K. Alpha-blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 128 U.K. Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 129 U.K. Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 130 U.K. Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 131 U.K. Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 132 U.K. Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
- Table 133 U.K. Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 134 U.K. Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
- Table 135 U.K. Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 136 U.K. Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 137 U.K. Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
- Table 138 U.K. Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
- Table 139 U.K. Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
- Table 140 U.K. Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 141 U.K. Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
- Table 142 U.K. Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
- Table 143 U.K. Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 144 U.K. Stroke Market, By Gender, 2021-2030 (Usd Thousand)
- Table 145 U.K. Stroke Market, By End User, 2021-2030 (Usd Thousand)
- Table 146 U.K. Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
- Table 147 France Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 148 France Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- Table 149 France Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
- List Of Figures
- Figure 1 Europe Stroke Market: Segmentation
- Figure 2 Europe Stroke Market: Data Triangulation
- Figure 3 Europe Stroke Market: Droc Analysis
- Figure 4 Europe Stroke Market : Europe Vs Regional Market Analysis
- Figure 5 Europe Stroke Market: Company Research Analysis
- Figure 6 Europe Stroke Market: Interview Demographics
- Figure 7 Europe Stroke Market: Dbmr Market Position Grid
- Figure 8 Europe Stroke Market: Market Application Coverage Grid
- Figure 9 Europe Stroke Market: Vendor Share Analysis
- Figure 10 Europe Stroke Market: Segmentation
- Figure 11 Increasing Number Of Patients With Hypertension And Coronary Heart Disease Is Expected To Drive The Europe Stroke Market Growth In The Forecast Period Of 2023 To 2030
- Figure 12 Ischemic Stroke Segment Is Expected To Account For The Largest Share Of The Europe Stroke Market In The Forecast Period Of 2023 & 2030
- Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The Europe Stroke Market
- Figure 14 Europe Stroke Market: By Type, 2022
- Figure 15 Europe Stroke Market: By Type, 2023-2030 (Usd Thousand)
- Figure 16 Europe Stroke Market: By Type, Cagr (2023-2030)
- Figure 17 Europe Stroke Market: By Type, Lifeline Curve
- Figure 18 Europe Stroke Market: By Treatment, 2022
- Figure 19 Europe Stroke Market: By Treatment, 2023-2030 (Usd Million)
- Figure 20 Europe Stroke Market: By Treatment, Cagr (2023-2030)
- Figure 21 Europe Stroke Market: By Treatment, Lifeline Curve
- Figure 22 Europe Stroke Market: By Diagnosis, 2022
- Figure 23 Europe Stroke Market: By Diagnosis, 2023-2030 (Usd Thousand)
- Figure 24 Europe Stroke Market: By Diagnosis, Cagr (2023-2030)
- Figure 25 Europe Stroke Market: By Diagnosis, Lifeline Curve
- Figure 26 Europe Stroke Market: By Gender, 2022
- Figure 27 Europe Stroke Market: By Gender, 2023-2030 (Usd Thousand)
- Figure 28 Europe Stroke Market: By Gender, Cagr (2023-2030)
- Figure 29 Europe Stroke Market: By Gender, Lifeline Curve
- Figure 30 Europe Stroke
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook